# US 12,214,004 B2 · Strains having effects of preventing or treating cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,214,004 B2
- Document ID: US12214004B2
- Status: Granted
- Kind: B2
- Application number: 17/096,031
- Filed: 2020-11-12
- Published: 2021-05-13
- Granted: 2025-02-04
- Earliest claimed: 2018-05-11
- Assignees: Genome and Company
- Applicants: Genome And Company
- Inventors: Hansoo Park; Shinyoung Park; Eun Ju Lee; Jae-Sung Yeon; Hye Hee Jeon; Wonduck Kim; Joo-Yeon Chung; Areum Jeong; Youn Kyung Houh; Jinyoung Sohn; Yun Yeon Kim; Sang Gyun Kim; Suro Lee
- Web page: https://patentgrep.com/patent/US12214004B2

## CPC

- A61K 35/745: Bifidobacteria
- A23K 10/18: of live microorganisms
- A23K 50/10: for ruminants
- A23K 50/20: for horses
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 1/205: Bacterial isolates
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12R 2001/46: Streptococcus {; Enterococcus; Lactococcus}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.

## Claims

### Claim 1

A pharmaceutical composition comprising a Bifidobacterium bifidum MG731 strain KCTC13452BP and a pharmaceutically acceptable excipient, and further comprising an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anticancer chemotherapeutic agent is selected from the group consisting of oxaliplatin, pemetrexed, cisplatin, gemcitabine, carboplatin, fluorouracil (5-FU), cyclophosphamide, paclitaxel, vincristine, etoposide, and doxorubicin.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anticancer immunotherapeutic agent is selected from the group consisting of anti-PD1, anti-PDL1, anti- CTLA, anti-Tim3, and anti-LAG3.

### Claim 4

A method for treating cancers, the method comprising administering an effective amount of a Bifidobacterium bifidum MG731 strain KCTC13452BP.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cancer is selected from the group consisting of lung cancer, colorectal cancer, gastric cancer, breast cancer, and liver cancer.

### Claim 6 (depends on 4)

The method of claim 4, wherein the Bifidobacterium bifidum MG731 strain exhibits an anticancer effect by decreasing the mobility of cancer cells.

### Claim 7 (depends on 4)

The method of claim 4, wherein the Bifidobacterium bifidum MG731 strain exhibits an anticancer effect by inhibiting the expression of angiogenic factors.

### Claim 8 (depends on 7)

The method of claim 7, wherein the angiogenic factors comprises one or more of the expression of VEGF (vascular endothelial growth factor), Ang1 (Angiopoietin1), or Ang2 (Angiopoietin2).

### Claim 9 (depends on 4)

The method of claim 4 further comprises administering an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the anticancer chemotherapeutic agent is selected from the group consisting of oxaliplatin, pemetrexed, cisplatin, gemcitabine, carboplatin, fluorouracil (5-FU), cyclophosphamide, paclitaxel, vincristine, etoposide, and doxorubicin.

### Claim 11 (depends on 9)

The method of claim 9, wherein the anticancer immunotherapeutic agent is selected from the group consisting of anti-PD1, anti-PDL1, anti-CTLA, anti-Tim3, and anti-LAG3.

### Claim 12 (depends on 9)

The method of claim 9, wherein the Bifidobacterium bifidum MG731 strain and the anticancer chemotherapeutic agent or the anticancer immunotherapeutic agent are administered simultaneously in one formulation, or are administered simultaneously or sequentially in separate formulations.

### Claim 13 (depends on 4)

The method of claim 4, wherein the cancer is selected from the group consisting of melanoma, squamous cell carcinoma, breast cancer, head and neck cancer, thyroid cancer, soft tissue sarcoma, osteosarcoma, testis cancer, prostate cancer, ovarian cancer, bladder cancer, skin cancer, brain cancer, angiosarcoma, mast cell tumor, leukemia, lymphoma, liver cancer, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colorectal cancer, hematopoietic tumor, neuroblastoma, epidermal carcinoma, or a metastatic cancer thereof.

### Claim 14 (depends on 4)

The method of claim 4, wherein the Bifidobacterium bifidum MG731 strain exhibits one or more of anticancer, anti-inflammatory, antioxidant, or immune enhancing effects.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Bifidobacterium bifidum MG731strain inhibits the expression of TNF-α.

### Claim 16

A food composition comprising a Bifidobacterium bifidum MG731 strain KCTC13452BP and a food additive.

### Claim 17

A method for ameliorating cancers, the method comprising administering an effective amount of a Bifidobacterium bifidum MG731 strain KCTC13452BP.